Top 4 NASDAQ Stocks In The Diagnostic Substances Industry With The Highest Revenue

Below are the diagnostic substances stocks on the NASDAQ in terms of revenue. The trailing-twelve-month revenue at IDEXX Laboratories

is $1.34 billion. IDEXX's PEG ratio is 2.10. The trailing-twelve-month revenue at Neogen

is $216.35 million. Neogen's ROE for the same period is 11.22%. The trailing-twelve-month revenue at Abaxis

is $188.77 million. Abaxis's operating margin for the same period is 14.31%. The trailing-twelve-month revenue at Meridian Bioscience

is $188.69 million. Meridian Bioscience had $40.36 million in total cash for the latest quarter.